Madrigal Pharmaceuticals Closer to EU Approval for First MASH Treatment, Rezdiffra

finance.yahoo.com/news/madrigal-pharmaceuticals-closer-eu-approval-164559780.html

In This Article:
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the best biotech stocks to invest in now. On June 20, Madrigal Pharmaceuticals moved closer to introducing the first treatment for metabolic dysfunction-associated steatohepatitis/MASH in Europe. The European…

This story appeared on finance.yahoo.com, 2025-06-24 16:45:59.
The Entire Business World on a Single Page. Free to Use →